 |
|
Drug inhibits neuroblastoma blood supply in pre-clinical tests
April 27, 2009SAN DIEGO - Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found a way to prevent blood vessels from aiding the growth of neuroblastoma, a childhood cancer. The pre-clinical study was presented today in a platform session at the 22nd annual meeting of the American Society of Pediatric Hematology/Oncology.
Investigators at the Children's Cancer Hospital at M. D. Anderson have discovered that the drug, AMD3100, hinders the formation of tumor blood vessels and reduces human neuroblastoma tumor growth by more than 75 percent in mice.
The drug blocks interaction between SDF-1a and its receptor CXCR4. This pathway plays an important role in signaling cells to different areas of the body. More specifically, the study suggests that SDF-1a plays a role in differentiating and/or attracting pericyte-like cells to neuroblastoma tumors.
Pericytes are essential for organizing blood vessels to feed tumors. Without pericytes, blood vessels are dysfunctional and tumors are left without a vital blood source. This study found that AMD3100 decreased the number of pericyte-like cells in neuroblastoma tumors by close to 90 percent.
"AMD3100 works by shutting down the process that tumors need to set up vascular systems," says Patrick Zweidler-McKay, M.D., Ph.D., assistant professor at the Children's Cancer Hospital and senior investigator on the study. "The drug doesn't kill neuroblastoma cells directly, but it prevents tumors from growing rapidly by disrupting their blood supply."
In tissue culture, investigators were also able to show how AMD3100 prevented neuroblastoma cells from migrating toward SDF-1a ligands. SDF-1a is present at high levels in the bone marrow, one of two areas where neuroblastoma most commonly metastasizes.
"There is the possibility that this therapy could help prevent neuroblastoma metastasis to the bone marrow. However, more studies are needed to investigate this theory," says Zweidler-McKay.
According to the American Cancer Society, approximately 650 children, mainly under the age of five, are diagnosed with neuroblastoma in the United States each year. Close to two-thirds of these children are diagnosed after the cancer has metastasized to other parts of the body. For these patients with high-risk neuroblastoma, long-term survival is less than 40 percent because the tumors are often resistant to traditional chemotherapy.
University of Texas M. D. Anderson Cancer Center
Pericytes are essential for organizing blood vessels to feed tumors. Without pericytes, blood vessels are dysfunctional and tumors are left without a vital blood source. This study found that AMD3100 decreased the number of pericyte-like cells in neuroblastoma tumors by close to 90 percent.
"AMD3100 works by shutting down the process that tumors need to set up vascular systems," says Patrick Zweidler-McKay, M.D., Ph.D., assistant professor at the Children's Cancer Hospital and senior investigator on the study. "The drug doesn't kill neuroblastoma cells directly, but it prevents tumors from growing rapidly by disrupting their blood supply."
In tissue culture, investigators were also able to show how AMD3100 prevented neuroblastoma cells from migrating toward SDF-1a ligands. SDF-1a is present at high levels in the bone marrow, one of two areas where neuroblastoma most commonly metastasizes.
"There is the possibility that this therapy could help prevent neuroblastoma metastasis to the bone marrow. However, more studies are needed to investigate this theory," says Zweidler-McKay.
According to the American Cancer Society, approximately 650 children, mainly under the age of five, are diagnosed with neuroblastoma in the United States each year. Close to two-thirds of these children are diagnosed after the cancer has metastasized to other parts of the body. For these patients with high-risk neuroblastoma, long-term survival is less than 40 percent because the tumors are often resistant to traditional chemotherapy.
University of Texas M. D. Anderson Cancer Center
Neuroblastoma Current Events and Neuroblastoma News RSSWeizmann Institute Scientists Discover A New Protein Partnership That Leads to Pediatric Tumor Regression
Why are some pediatric cancers able to spontaneously regress? Prof. Michael Fainzilber and his team of the Weizmann Institute's Biological Chemistry Department seem to have unexpectedly found part of the answer.
PET Can Help Guide Treatment Decisions for a Common Pediatric Cancer
A new study published in the August issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET) is an important tool for depicting the extent of neuroblastoma in some patients, particularly for those in the early stages of the disease.
Protein That Promotes Cancer Cell Growth Identified
Scientists at Burnham Institute for Medical Research (Burnham) have found that the Caspase-8 protein, long known to play a major role in promoting programmed cell death (apoptosis), helps relay signals that can cause cancer cells to proliferate, migrate and invade surrounding tissues.
U of M Researchers Find Childhood Cancer Risk Rises with Mother's Age
Research from the Masonic Cancer Center, University of Minnesota indicates that a baby born to an older mother may have a slightly increased risk for many of the cancers that occur during childhood.
Variations in 5 genes raise risk for most common brain tumors
Common genetic variations spread across five genes raise a person's risk of developing the most frequent type of brain tumor, an international research team reports online in Nature Genetics.
Genetic finding could lead to targeted therapy for neuroblastoma
Researchers have identified a genetic glitch that could lead to development of neuroblastoma, a deadly form of cancer that typically strikes children under 2.
Researchers identify gene that regulates tumors in neuroblastoma
Virginia Commonwealth University researchers have identified a gene that may play a key role in regulating tumor progression in neuroblastoma, a form of cancer usually found in young children.
New therapy enlists immune system to boost cure rate in a childhood cancer
A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the nervous system.
Immunotherapy effective against neuroblastoma in children
A phase III study has shown that adding an antibody-based therapy that harnesses the body's immune system resulted in a 20 percent increase in the number of children living disease-free for at least two years with neuroblastoma.
Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have discovered a new drug combination that significantly hinders tumor growth in neuroblastoma, a childhood cancer.
More Neuroblastoma Current Events and Neuroblastoma News Articles
 |
Neuroblastoma by Nai-Kong V. Cheung (Editor), Susan L. Cohn (Editor) Neuroblastoma is a medical enigma. As a childhood neoplasm arising from neural crest cells, it is characterized by diverse clinical behaviors ranging from spontaneous remission to rapid tumor progression and death. Although clinical outcome can be predicted to a large extent by the stage of disease and the age at diagnosis, an in-depth understanding of its clinico-pathological behavior, now greatly aided by sophisticated molecular genetic profiling, will improve diagnostic precision and refine risk-based therapies. Comprehensive international efforts have advanced our understanding of tumor biology, and improved the clinical management of children with neuroblastoma. This book reviews our current understanding of the genes and biological pathways that contribute to neuroblastoma... |
 |
Neuroblastoma by Velvet Acid Christ |
 |
Neuroblastoma Awareness Ribbon Mouse Pad by MyHeritageWear.com The Neuroblastoma Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Neuroblastoma Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Neuroblastoma Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Fight Against Neuroblastoma Sweatshirt X-Large White by Shop Zeus |
 |
Cure Neuroblastoma Keychain by Design a Product LLC Text on keychain: Cure Neuroblastoma * Durable acrylic key chain is crystal-clear and double-sided so the artwork or message is seen twice. * Sturdy metal ring holds your keys securely. * Full color printed images or messages are included. * If you have new ideas or need help selecting text for your custom keychains please contact us. * Size: 2 1/8" x 3 1/2" (Approx. business card) |
![Neuroblastoma Injected By Viral Oestogena [Explicit]](http://ecx.images-amazon.com/images/I/41anx1tCcwL._SL160_.jpg) |
Neuroblastoma Injected By Viral Oestogena [Explicit] Thorwald / Pulmonary Fibrosis (Primary Contributor) |
 |
Neuroblastoma Research Trends by Lucas H. Andre (Editor), Nathan E. Roux (Editor) Neuroblastoma is a cancer that develops from nerve cells found in several areas of the body. Neuroblastoma most commonly affects children age 5 or younger, though it may rarely occur in older children and adults. Neuroblastoma is the most common cancer in babies. Neuroblastoma develops in tissue that makes up the sympathetic nervous system - the system of nerves that automatically regulates your heart rate, blood pressure and digestion. Neuroblastoma most commonly arises in and around the adrenal glands, which sit atop the kidneys. However, neuroblastoma can also develop in other areas of the abdomen and in the chest, neck and pelvis. This book presents important new research in this field of research. |
|
EM-1. Metastatic neuroblastoma presenting as a basilar skull fracture in a child.(Section on Emergency Medicine): An article from: Southern Medical Journal by Antonio E. Muniz (Author), Hani Mowafi (Author) This digital document is an article from Southern Medical Journal, published by Southern Medical Association on October 1, 2004. The length of the article is 645 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: EM-1. Metastatic neuroblastoma presenting as a basilar skull fracture in a child.(Section on Emergency Medicine) Author: Antonio E. Muniz Publication: Southern Medical Journal (Refereed) Date: October 1, 2004 Publisher: Southern Medical Association Volume: 97 Issue: 10 Page: S47(1) Distributed by Thomson... | |
 |
Cure Neuroblastoma Long Sleeve T-shirt Large White by Shop Zeus |
 |
Beating Neuroblastoma Together Mug by Design a Product LLC Text on mug: Beating Neuroblastoma Together * Custom coffee mugs are dishwasher-safe and microwave-safe. Colors are permanently baked into the mug''s surface. * If you have new ideas or need help selecting text for your custom coffee mugs please contact us. * Size: 11 oz. capacity ceramic coffee mug. |
| © 2009 BrightSurf.com |